testing facilities or external contract laboratories under defined conditions.

2. Scope

This procedure applies to all analytical methods (qualitative and quantitative) developed or transferred within the Analytical Method Development (AMD) department and tested at more than one site, including partner CROs, CDMOs, or manufacturing QC laboratories.

3. Responsibilities

• Method Developer: Coordinates comparability studies and ensures test protocols are standardized across sites.
• Participating Labs: Perform testing as per unified protocol and submit raw data.
• QA Representative: Verifies protocol compliance and ensures data integrity.
• AMD Manager: Reviews outcomes and authorizes final comparability report.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that inter-laboratory comparability exercises are executed and documented as per regulatory expectations and internal quality systems.

5. Procedure

5.1 Selection of Laboratories

1. Identify Receiving Units (RUs) based on their analytical capability and regulatory compliance history.
2. Ensure all laboratories have access to required instrumentation, reference standards, and controlled environments.

5.2 Development of Test Protocol

1. Prepare a detailed comparability protocol outlining the following:
• Scope and objective of the study
• Test method(s), matrices, concentrations
• Number of replicates per lab
• Acceptance criteria for each parameter
• Statistical tools to be used for evaluation
2. Obtain QA approval before initiation.

5.3 Sample Distribution and Control

1. Label and ship homogenized samples from a single batch to each site with COA and stability data.
2. Document chain of custody and confirm storage and handling conditions at each lab.

5.4 Data Collection and Analysis

1. Each site performs testing using identical method SOPs and documentation practices.
2. Collect results for critical parameters (e.g., assay, impurities, dissolution, pH, etc.).
3. Analyze results using tools like ANOVA, TOST, or Bland-Altman to assess inter-lab variability.
4. Document findings in Annexure-1 with a focus on %RSD, bias, and statistical equivalence.

5.5 Resolution of Discrepancies

1. Investigate outliers or discrepancies through deviation forms and RCA.
2. Perform repeat testing if required under QA observation.
3. Update CAPA register with corrective actions, training plans, or method revisions.

5.6 Final Report Preparation

1. Compile a unified report including protocol, raw data, comparative charts, and statistical evaluations.
2. Summarize conclusions with respect to acceptance criteria fulfillment and reproducibility.
3. Get report reviewed by QA and approved by AMD Head.
4. Archive report in electronic document management system (EDMS).

6. Abbreviations

• AMD: Analytical Method Development
• RU: Receiving Unit
• QA: Quality Assurance
• RCA: Root Cause Analysis
• CAPA: Corrective and Preventive Action

7. Documents

1. Annexure-1: Inter-Lab Data Summary Table
2. Annexure-2: Protocol Template
3. Annexure-3: Deviation Log
4. Annexure-4: Final Report Format

8. References

• ICH Q2(R1) – Validation of Analytical Procedures
• ICH Q9 – Quality Risk Management
• USP General Notices and Requirements
• FDA Guidance for Industry: Analytical Procedures and Methods Validation

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name	Pravin Mishra	Ritu Agarwal	Dr. Neeraj Kulkarni
Designation	AMD Scientist	QA Manager	Head – Analytical Method Development
Department	Analytical Method Development	Quality Assurance	Analytical Method Development

11. Annexures

Annexure-1: Inter-Laboratory Data Summary

Lab	Assay Result (%)	Impurities (%)	Dissolution (%)	pH
Site A	99.3	0.2	97.5	6.8
Site B	98.9	0.25	98.0	6.9
Site C	99.1	0.22	97.8	6.7

Annexure-2: Protocol Template

Includes objectives, scope, acceptance criteria, test parameters, statistical tools, and reporting structure for inter-lab method comparison.

Annexure-3: Deviation Log

Deviation ID	Observation	Root Cause	Corrective Action	Status
DEV-346-01	High impurity result at Site B	Instrument calibration delay	Recalibration and training	Closed

Annexure-4: Final Report Format

Summary of method performance across labs, graphical comparison, ANOVA output, and conclusion on method reproducibility.

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
01/06/2025	2.0	Added ANOVA and graphical tools in assessment	Annual SOP Review	Dr. Neeraj Kulkarni
20/04/2022	1.0	Initial version	New SOP introduction	QA Head